论文部分内容阅读
目的在以清湿化瘀为治法的内异康复片被广泛应用于治疗子宫腺肌病(AM)和前期实验研究的基础上,运用同种异体垂体植入子宫的方法建立AM实验模型,采用免疫组化的技术检测PTEN、P-P65在AM治疗前后各组小鼠在位及异位子宫内膜上的表达差异,探究AM的发病机制。方法采用异体垂体移植法造模,随机设内异康复片低、中、高剂量组,孕三烯酮组,丹莪妇康煎膏组,模型组。饲养3月后分别灌胃3月治疗,免疫组化法观察治疗前后在位、异位子宫内膜上PTEN、P-P65差异。结果不同方法治疗后PTEN表达均增高,显著高于模型组(P<0.001),内异康复片高剂量组优于其他各治疗组(P<0.001);P-P65表达均下降,显著低于模型组(P<0.001),内异康复片高剂量组优于其他各治疗组(P<0.001)。结论内异康复片可上调PTEN,下调P-P65的表达,从而达到控制和治疗子宫腺肌病及其临床症状的目的。
Objective The purpose of this study was to establish an experimental model of AM with allopathic rehabilitation tablets treated by the method of clearing away dampness and removing blood stasis and being widely used in the treatment of adenomyosis (AM) and previous experimental studies. The expression of PTEN and P-P65 in eutopic and ectopic endometrium of mice in each group before and after AM was detected by immunohistochemical technique to explore the pathogenesis of AM. Methods Allogeneic pituitary grafting was used to establish models of low, middle and high doses of Neiyi Kangfu tablets, gestrinone group, Dancaofukang ointment group and model group. After feeding for 3 months, respectively, gavage March treatment, immunohistochemistry before and after treatment of eutopic and ectopic endometrium PTEN, P-P65 differences. Results The expression of PTEN increased with the different treatment methods (P <0.001), but the expression of P-P65 was significantly lower than that of the other treatment groups (P <0.001) Model group (P <0.001), Nei Yi Kang Tablet high-dose group than the other treatment groups (P <0.001). Conclusion Neiyi Kangpian Tablet can up-regulate PTEN and down-regulate the expression of P-P65 in order to achieve the goal of controlling and treating adenomyosis and its clinical symptoms.